6 Meridian’s Corcept Therapeutics CORT Stock Holding History

6 Meridian’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$201K	Buy	10,149 +96	+1%	+$1.95K	0.01%	395
2021 Q3	$198K	Sell	10,053 -3,646	-27%	-$76.3K	0.02%	381
2021 Q2	$301K	Buy	13,699 +151	+1%	+$3.36K	0.02%	225
2021 Q1	$322K	Sell	13,548 -3,599	-21%	-$96.1K	0.03%	219
2020 Q4	$449K	Sell	17,147 -173	-1%	-$3.65K	0.04%	160
2020 Q3	$301K	Buy	+17,320	New	+$276K	0.03%	185
2019 Q1	–	Sell	-14,787	Closed	-$198K	–	446
2018 Q4	$198K	Sell	14,787 -156	-1%	-$2.06K	0.02%	385
2018 Q3	$210K	Buy	+14,943	New	+$209K	0.02%	401

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

6 Meridian's CORT Position: Q4 2021 in Review

6 Meridian increased its Corcept Therapeutics (CORT) stake by 0.95% in Q4 2021, buying an estimated $1.95K and bringing the position to 10,149 shares worth $201K. The position accounts for 0.01% of the portfolio, ranked #395.

6 Meridian first reported a position in CORT in Q3 2018 and has held it in 8 quarters since. The position peaked at $449K in Q4 2020. 208 funds tracked by Wall St. Rank hold CORT as of Q4 2021.

6 Meridian held 10,149 shares of Corcept Therapeutics worth $201K as of Q4 2021.
6 Meridian bought 96 Corcept Therapeutics shares in Q4 2021, an estimated $1.95K.
Corcept Therapeutics made up 0.01% of 6 Meridian's portfolio in Q4 2021, its #395 holding.
6 Meridian first reported a position in Corcept Therapeutics in Q3 2018 and has held it in 8 quarters since.
6 Meridian's Corcept Therapeutics position peaked at $449K in Q4 2020.
208 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2021.

Based on 6 Meridian's 13F filing for Q4 2021, filed 1 Feb 2022.